|
|
|
07 Mar 2008 |
Marcadia Biotech and Merck & Co., Inc. (MRK) Enter Strategic Collaboration
|
|
07 Mar 2008 |
Lilly Announces Termination of AIR Insulin Program
|
|
03 Mar 2008 |
NeuroSearch publishes positive and confirmatory results from TIPO-2, a clinical metabolic study with tesofensine for the treatment of obesity
|
|
28 Feb 2008 |
Metabasis Therapeutics Completes Enrollment of Its Proof-of-Concept Clinical Trial for MB07803, Its Product Candidate for the Treatment of Type 2 Diabetes
|
|
28 Feb 2008 |
Savient Provides Further Information on Top Line Phase 3 Trials Results for Puricase(R) (pegloticase)
|
|
27 Feb 2008 |
Athersys Announces Summary Results for Phase 1 Safety Study of Its Novel Obesity Drug
|
|
26 Feb 2008 |
NPIL Research & Development Limited commences Phase I trials on new molecule for metabolic disorders in Europe
|
|
25 Feb 2008 |
Inkerin Pharmaceutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
|
|
25 Feb 2008 |
Akesis Pharmaceuticals Doses First Patient in Phase IIa Trial of AKP-020 for Type 2 Diabetes
|
|
25 Feb 2008 |
Eucreas(R), a single-tablet combination of Galvus(R) and metformin, set for launch in first EU countries as new treatment for type 2 diabetes
|
|
22 Feb 2008 |
FORSTEO(R) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis
|
|
20 Feb 2008 |
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
|
|
20 Feb 2008 |
ConjuChem Initiates Phase II Study of PC-DAC(TM):Exendin-4
|
|
20 Feb 2008 |
Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
|
|
12 Feb 2008 |
Unigene Announces Publication of Initial Results of Site-Directed Bone Growth Studies
|
|
12 Feb 2008 |
Phase III program for AVE0010/ZP10 licensed from Zealand Pharma A/S will begin in the first quarter of 2008
|
|
11 Feb 2008 |
Bentley Pharmaceuticals Announces Completion of Treatment in Phase II India Clinical Study in Type 2 Diabetes and Preliminary Clinical Results
|
|
11 Feb 2008 |
Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin
|
|
06 Feb 2008 |
7TM Pharma announces the selection of a new pre-clinical development candidate, TM38837, for treatment of obesity and Type 2 diabetes
|
|
01 Feb 2008 |
Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches
|
|
01 Feb 2008 |
Glenmark Pharmaceuticals to get back the Global Rights to Melogliptin, GRC 8200 from Merck Serono
|
|
01 Feb 2008 |
Analytical Results for Women from Large Scale Clinical Trial MEGA Study Employing the Hypercholesterolemia Drug Mevalotin(R) Published
|
|
30 Jan 2008 |
Phosphagenics reports superior pre-clinical cholesterol results from APA-01 and atorvastatin combination
|
|
29 Jan 2008 |
Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
|
|
29 Jan 2008 |
Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
|
|
29 Jan 2008 |
Tranzyme Pharma Receives IND Clearance for Its Oral Ghrelin Agonist, TZP-102, for the Treatment of Gastroparesis
|
|
25 Jan 2008 |
TransTech Pharma, Inc. Acquires Three Programs for the Treatment of Metabolic Disorders from Novo Nordisk
|
|
25 Jan 2008 |
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
|
|
25 Jan 2008 |
Merck Receives Not Approvable Letter from FDA for OTC MEVACOR(R) (lovastatin) 20 mg
|
|
24 Jan 2008 |
GlaxoSmithKline to revise Avandia(R) (rosiglitazone maleate) label in Europe following assessment by CHMP
|
|
24 Jan 2008 |
Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
|
|
24 Jan 2008 |
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
|
|
22 Jan 2008 |
Tercica initiates phase II clinical trial with next-generation growth hormone product for the treatment of short stature
|
|
22 Jan 2008 |
Ambrilia Reports Positive Phase III Preliminary Results Showing the Safety and Efficacy of its Prolonged-Release Formulation of Octreotide
|
|
22 Jan 2008 |
Oramed Pharmaceuticals Commences Phase 1B Clinical Trials
|
|
22 Jan 2008 |
Highly Promising Results for New GW Cannabinoid Treatments for Diabetes and Related Metabolic Disorders
|
|
18 Jan 2008 |
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in
|
|
17 Jan 2008 |
Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
|
|
15 Jan 2008 |
Ligand Partner Pfizer Submits NDA for Fablyn(R)
|
|
15 Jan 2008 |
First Head to Head Study Comparing CRESTOR(TM) and LIPITOR(R) Effects on the Treatment of Atherosclerosis
|
|
14 Jan 2008 |
Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
|
|
14 Jan 2008 |
Novo Nordisk refocuses its activities within inhaled insulin and discontinues the development of AERx(R)
|
|
08 Jan 2008 |
Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
|
|
08 Jan 2008 |
Pennington Biomedical Research Institute Receives FDA Approval to Begin Phase I Studies of Compellis Pharmaceuticals' Novel and Patented Obesity Therapy
|
|
07 Jan 2008 |
OREXIGEN(TM) Therapeutics Reports 48-Week Results of Phase IIb Trial of Empatic(TM) to Treat Obesity
|
|
07 Jan 2008 |
Amicus Therapeutics Announces Positive Interim Results From Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
|
|
07 Jan 2008 |
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
|
|
07 Jan 2008 |
Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
|
|
07 Jan 2008 |
Neurogen Announces Results of Multiple Ascending Dose Studies with Experimental Obesity Drug
|
|
07 Jan 2008 |
Sirtris Announces Positive Results with Proprietary Version of Resveratrol, SRT501, in a Phase 1b Type 2 Diabetes Clinical Study
|
| |
|
Results 251 - 300 of 1041 |
